Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 08, 2025

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 05, 2025

The Top 5 Biosimilar Articles for the Week of June 30

July 04, 2025

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 03, 2025

Posters Show Efficacy for Combination Therapies With Trastuzumab Biosimilars in Breast Cancer

January 4th 2024

By Skylar Jeremias

Article

Posters from San Antonio Breast Cancer Symposium 2023 found that combination therapies featuring trastuzumab biosimilars and other common cancer medicines were safe and effective in patients with breast cancer.

Biosimilar SB5 Matches Originator in Safety, Efficacy for Inflammatory Diseases After Switching

January 3rd 2024

By Cameron Santoro

Article

Adults with inflammatory diseases maintained disease control when transitioning from originator adalimumab (Humira) to biosimilar SB5 in a pan-European study.

Developers’ Perspective on Streamlining the Biosimilar Development Process

January 2nd 2024

By Deana Ferreri, PhD

Article

The regulatory structure of biosimilar development can be safely streamlined and made more efficient and less costly, wrote authors from Sandoz, Fresenius Kabi, Boehringer Ingelheim, and Samsung Bioepis in an opinion article published in BioDrugs.

The Top 5 Most-Read Rheumatology Stories of 2023

January 1st 2024

By Skylar Jeremias

Article

The top 5 most-read rheumatology stories of 2023 included the changing market dynamics in the adalimumab space, including new launches and interchangeability labels, as well as the addition of Stelara and Enbrel to the list of originators up for Medicare price negotiation.

A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond

December 31st 2023

By Skylar Jeremias

Podcast

On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.

The Top 5 Most-Read Regulatory Stories of 2023

December 30th 2023

By Skylar Jeremias

Article

The top 5 most-read regulatory stories of 2023 covered the FDA approvals for the first ustekinumab biosimilar and the first subcutaneous infliximab product, as well as other regulatory updates.

The Top 5 Biosimilar Articles of 2023

December 29th 2023

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for 2023.

The Top 5 Most-Read Conference Stories of 2023

December 28th 2023

By Skylar Jeremias

Article

The top 5 most-read conference stories of 2023 recapped some of big biosimilar takeaways from this year’s conferences, including insight into how geopolitics will impact the industry, efforts from government agencies, and strategies to increase biosimilar uptake.

The Top 5 Most-Read Oncology Stories of 2023

December 27th 2023

By Skylar Jeremias

Article

The top 5 most-read oncology stories of 2023 include the US market launch of Fylnetra, the sixth pegfilgrastim biosimilar on the market, the FDA approval for an autoinjector pegfilgrastim biosimilar, and more.

The Top 5 Most-Listened Podcasts of 2023

December 26th 2023

By Skylar Jeremias

Article

The top 5 most-listened podcast episodes of 2023 covered a range of topics including the US market introduction of adalimumab biosimilars, current market trends, the role of providers in boosting adoption rates, and more.